SARS-CoV-2 Viral Kinetics and Host Immune Responses
Conditions
Brief summary
This single-center prospective observational study will examine immune responses to to SARS-CoV-2 and how they correlate with its virological characteristics and clinical manifestations in infected patients. Household contacts will also be included so that early immune responses and viral kinetics can be captured. Patients and contacts will be followed for 8 and 2 weeks, respectively. The study will include a maximum of 250 participants.
Detailed description
The primary aim of this single-center prospective observational study is to establish how immune responses to SARS-CoV-2 or to cross-reactive viruses correlate with the virological and clinical characteristics of SARS- CoV-2-infected patients and their exposed household contacts. Through iterative sampling, the viral kinetics of at least 50 infected patients will be evaluated in relation to symptom severity and innate and adaptive immune responses, while their household contacts will be observed for viral detection and immune responses. Patients and contacts will be followed for 8 and 2 weeks, respectively. The study will include a maximum of 250 participants.
Interventions
OTHERNA (no intervention)
NA (no intervention)
Sponsors
University of Geneva, Switzerland
University Hospital, Geneva
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Inclusion criteria
The following persons may be included: * A patient of any age meeting the European Centre for Disease Control and Prevention's confirmed case definition: A person with laboratory confirmation of virus causing COVID-19, irrespective of clinical signs and symptoms (and/or high suspicion/actively being treated as CoVID+ cases pending test confirmation) * Household contacts (defined as those sleeping in the same apartment/house as an infected patient) of a patient with laboratory-confirmed COVID-19 (and/or high suspicion/actively being treated as CoVID+ cases pending test confirmation), whether symptomatic or not, and whether testing positive or not during a period of 14 days Exclusion Criterion: * Long-term incapacity leading to the inability to provide informed consent while not having a patient representative with the ability to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity primary outcome: Geometric mean antibody concentration of total IgG antibodies to SARS-CoV-2 assessed by ELISA at 28 days | assessed at 28 days after diagnosis/presumed diagnosis | Geometric mean antibody concentration of total IgG antibodies to SARS-CoV-2 assessed by ELISA at 28 days after diagnosis/suspected diagnosis |
| Virologic primary outcome: Peak viral load in the 56 days following diagnosis/suspected diagnosis | 56 days after diagnosis/presumed diagnosis | Peak viral load in the 56 days following diagnosis/suspected diagnosis, quantified by real-time reverse-transcriptase polymerase chain reaction (RT-PCR) on nasopharyngeal swabs. |
Countries
Switzerland
Outcome results
None listed